Topotecan Uses, Dosage, Side Effects and Interactions
Hycamtin
Hycamtin was the first topotecan product the FDA approved, in May 1996. A generic is listed for its injections, but not for its capsules.
Topotecan is a chemotherapy medicine (a topoisomerase inhibitor) used to treat small cell lung cancer, metastatic ovarian cancer and cervical cancer, depending on the product.
Quick links
Ask Anything About TopotecanType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Topotecan in Short
- Drug class Topoisomerase Inhibitor How the FDA classifies it
What it treatsTopotecan is used for several cancers. Which ones depend on the product. Topotecan injection (IV): small cell lung cancer (SCLC) that was platinum-sensitive and progressed at least 60 days after first-line chemotherapy started.
- How you get it Prescription only
- Comes asInjection and capsuleAvailable strengths
Injection (into a vein)
- 4 mg/4 mL
Capsule (by mouth)
- 0.25 mg
- 1 mg
- Crushing or chewingSome forms are on our Do Not Crush list Listed: Hycamtin (capsule); Topotecan hydrochloride (capsule)
- The FDA’s strongest warningBoxed warning The FDA’s most serious alert. Read what it says
- Supplements and herbs19 interact 1 major, 9 moderate and 9 minor
- Generic versionYes, FDA-approved Listed with the FDA, which does not mean every pharmacy stocks it
The Pharmacist’s Take
Topotecan (Hycamtin) is a chemotherapy drug for small cell lung cancer and, as an injection, ovarian and cervical cancer, usually a later option after earlier chemotherapy fails; it blocks topoisomerase I, an enzyme cancer cells need to copy DNA, leaving breaks they cannot repair, and it has been around since about 1996, with FDA-approved generics listed. Like most chemotherapy it is hard going, and tiredness, nausea and hair loss are what people notice most. The one thing to watch is its boxed warning for severe myelosuppression (a serious drop in blood counts), so call your care team right away about fever, chills, or unusual bleeding or bruising.
Key Takeaways From the HelloPharmacist Team
- Expect 21-day cycles, given as a 30-minute IV infusion on the first few days or as capsules once daily for 5 days.
- Plan on frequent blood tests, because each new cycle starts only once your white cells and platelets have recovered enough.
- Get help right away for fever with belly pain, or a new cough with trouble breathing, which can signal bowel or lung inflammation.
- Use effective birth control during treatment and for 6 months after (3 months for men), because topotecan can harm an unborn baby.
FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about Topotecan.
Hycamtin can cause severe myelosuppression, meaning a serious drop in your blood cell counts. Your first cycle should only be given if your neutrophil (infection-fighting white cell) and platelet counts are high enough at the start. Your blood counts will be checked regularly. Tell your care team right away about fever, signs of infection, or unusual bleeding or bruising.
Patient Information Guide for Topotecan
What It’s Used For
Topotecan treats several cancers, depending on the product.
- Metastatic ovarian cancer after progression on or after earlier chemotherapy (Hycamtin for injection and topotecan hydrochloride for injection, as a single agent).
- Small cell lung cancer (SCLC) that was platinum-sensitive and progressed at least 60 days after first-line chemotherapy started (topotecan injection products and Hycamtin for injection).
- Relapsed SCLC in people with a prior complete or partial response who are at least 45 days from the end of first-line chemotherapy (Hycamtin capsules).
- Stage IV-B, recurrent or persistent cervical cancer not amenable to curative treatment, together with cisplatin (Hycamtin for injection, topotecan hydrochloride for injection and one topotecan injection).
How It Works
Topotecan attaches to topoisomerase I, an enzyme that normally nicks and reseals DNA so it can be copied. By stopping the reseal step, topotecan causes double-strand DNA damage when cells copy their DNA. Cells cannot easily repair this damage, which is thought to be how it kills cancer cells.
Drug Class
Drug Class
- Topoisomerase Inhibitor
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.
Drug Class
Established Pharmacologic Class (EPC)- Topoisomerase Inhibitor
The main drug class the FDA gives it. It is the class named on the drug’s label.
How It Works
Mechanism of action (MoA)- Topoisomerase Inhibitors
What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.
What It Does in the Body
Physiologic effect (PE)None listed for Topotecan in the FDA’s index.
From our Patient Information GuideTopotecan attaches to topoisomerase I, an enzyme that normally nicks and reseals DNA so it can be copied. By stopping the reseal step, topotecan causes double-strand DNA damage when cells copy their DNA. Read How Topotecan Works
A change it makes in how the body works.
Chemical Family
Chemical structure (CS)None listed for Topotecan in the FDA’s index.
The chemical family it belongs to, by its structure.
Drug Family
WHO ATC classification- Topoisomerase 1 (TOP1) inhibitors
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.
Dosage
Topotecan is given in repeating 21-day cycles, with dosing based on your body size.
- Injection: given into a vein over about 30 minutes by a healthcare team, usually for several days at the start of each cycle.
- Hycamtin capsules: taken by mouth once a day for 5 days, with or without food. Swallow whole.
- Missed or vomited dose (capsules): do not take an extra dose. Take the next one at the scheduled time.
Doses may be lowered for low blood counts, diarrhea (capsules) or kidney problems. Follow your prescriber and the label.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Topotecan Injection
Ovarian cancer that has spread
For adults
Usual dose 1.5 mg/m2 by IV infusion over 30 minutes daily for 5 days
- 1.5 mg/m2 by intravenous infusion over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity
Limit Do not exceed a single dose of 4 mg intravenously
IV means given into a vein (intravenous).
Small cell lung cancer
For adults
Usual dose 1.5 mg/m2 by IV infusion over 30 minutes daily for 5 days
- 1.5 mg/m2 by intravenous infusion over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day cycle
Limit Do not exceed a single dose of 4 mg intravenously
IV means given into a vein (intravenous).
Cervical cancer
For adults
Usual dose 0.75 mg/m2 by IV infusion over 30 minutes daily on Days 1, 2, and 3
- 0.75 mg/m2 by intravenous infusion over 30 minutes daily on Days 1, 2, and 3, with cisplatin 50 mg/m2 on Day 1, of a 21-day cycle
Limit Do not exceed a single dose of 4 mg intravenously
IV means given into a vein (intravenous).
Single agent, kidney problems with creatinine clearance 20 to 39 mL/min
For adults
Dose 0.75 mg/m2/day
- Reduce the dose to 0.75 mg/m2/day
Good to know
Creatinine clearance calculated with Cockcroft-Gault method using ideal body weight
Topotecan Taken by Mouth
Small cell lung cancer
Adults Usual dose 2.3 mg/m2 once a day for 5 days
Step by step
- 2.3 mg/m2/day orally once daily, with or without food, for 5 consecutive days, starting on Day 1 of a 21-day cycle
- Round to the nearest 0.25 mg
Good to know
Swallow capsules whole; same number of capsules each of the 5 days
Capsules, kidney problems with creatinine clearance less than 30 mL/min Usual dose 0.6 mg/m2 once a day
Good to know
Cockcroft-Gault with ideal body weight
Adults with kidney problems (creatinine clearance 30 to 49 mL/min) Usual dose 1.5 mg/m2 once a day
Good to know
Cockcroft-Gault with ideal body weight
Side Effects
Many side effects come from effects on the blood and digestive system.
Common side effects
- Low white blood cell count (neutropenia, leukopenia)
- Low red blood cell count (anemia)
- Low platelet count (thrombocytopenia)
- Nausea and vomiting
- Diarrhea or constipation
- Hair loss
- Tiredness or weakness
- Fever and pain
When to get medical help
- Call your care team right away for fever, chills or other signs of infection, since low white blood cells can lead to serious infection or sepsis.
- Get help for fever with belly pain, which can signal neutropenic colitis (inflamed bowel linked to low white cells). This can be fatal.
- Report new cough, fever or trouble breathing, which can be signs of interstitial lung disease (lung inflammation).
- Tell your team about unusual bleeding or bruising, which can come with low platelets.
- Seek help for signs of a severe allergic reaction, such as swelling or severe itching.
- Tell the nurse right away about pain, swelling or redness at the IV site, since leakage of the drug outside the vein (extravasation) can occur.
- For Hycamtin capsules, report severe diarrhea, as treatment may need to be held.
Warnings and Precautions
- Bone marrow suppression is the biggest risk, with severe drops in white cells, red cells and platelets. Counts are checked often.
- Neutropenic colitis: low white cells can lead to bowel inflammation, which has been fatal.
- Interstitial lung disease: reported, some cases fatal. Risk is higher with prior lung disease, lung cancer or chest radiation.
- Pregnancy: can cause fetal harm.
- Extravasation: the IV drug leaking outside the vein has been seen, mostly mild but sometimes severe.
- Diarrhea (capsules): Hycamtin capsules are not given during severe diarrhea.
Interactions
Combining topotecan with other drugs that lower blood counts needs care.
- Cisplatin and other chemotherapy: more severe bone marrow suppression, so doses may be reduced.
- Platinum timing: giving a platinum drug on day 1 required lower doses than on day 5.
- G-CSF: starting it too early can prolong neutropenia, so it is not started until day 6, 24 hours after the last topotecan dose.
Interactions Listed in the FDA-Approved Label
From the Topotecan prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
-
What happensConcomitant administration of G-CSF can prolong the duration of neutropenia.What to doDo not start G-CSF until day 6 of the course, 24 hours after completing topotecan.
-
Platinum agents For example: cisplatin, carboplatinWhat happensMyelosuppression was more severe with cisplatin in Phase 1 trials, and a sequence-dependent interaction was reported; giving the platinum agent on day 1 required lower doses of each agent than giving it on day 5.What to doA dose reduction may be necessary.
-
Other cytotoxic agentsWhat happensGreater myelosuppression is likely when used in combination with other cytotoxic agents.What to doA dose reduction is necessary.
Read the label’s full interactions text
7 DRUG INTERACTIONS G-CSF: Concomitant administration of G-CSF can prolong the duration of neutropenia, so if G-CSF is to be used, do not initiate it until day 6 of the course of therapy, 24 hours after completion of treatment with topotecan hydrochloride for injection. Platinum and Other Cytotoxic Agents: Myelosuppression was more severe when topotecan hydrochloride for injection, at a dose of 1.25 mg/m 2 /day for 5 days, was given in combination with cisplatin at a dose of 50 mg/m 2 in Phase 1 trials. In one trial, 1 of 3 patients had severe neutropenia for 12 days and a second patient died with neutropenic sepsis. Greater myelosuppression is also likely to be seen when topotecan hydrochloride for injection is used in combination with other cytotoxic agents, thereby necessitating a dose reduction. However, when combining topotecan hydrochloride for injection with platinum agents (e.g., cisplatin or carboplatin), a distinct sequence-dependent interaction on myelosuppression has been reported. Coadministration of a platinum agent on day 1 of dosing with topotecan hydrochloride for injection required lower doses of each agent compared to coadministration on day 5 of the dosing schedule for topotecan hydrochloride for injection. For information on the pharmacokinetics, efficacy, safety, and dosing of topotecan hydrochloride for injection at a dose of 0.75 mg/m 2 /day on days 1, 2, and 3 in combination with cisplatin 50 mg/m 2 on day 1 for cervical cancer, see Dosage and Administration, Adverse Reactions, Clinical Pharmacology, and Clinical Studies. Do not initiate G-CSF until 24 hours after completion of treatment with topotecan hydrochloride for injection. Concomitant administration can prolong duration of neutropenia. Greater myelosuppression is likely to be seen when used in combination with other cytotoxic agents.
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- Do not use with a history of severe allergic reaction to topotecan or its ingredients.
- Topotecan injection should not be used with severe bone marrow depression.
- Blood counts must be high enough before the first cycle.
- Pregnancy should be ruled out before starting. Use effective contraception during treatment (6 months after for women, 3 months after for men).
- Do not breastfeed during treatment and for 1 week after the last dose.
- Kidney function matters, as doses are lowered for reduced kidney function.
- Not established for children. Older adults had no overall differences in safety or effectiveness.
- Tell your doctor about lung disease or prior chest radiation.
Overdose
The main problem with too much topotecan is bone marrow suppression. Mouth sores, higher liver enzymes, and severe infection have also been reported. There is no known antidote. Treatment is monitoring blood counts and supportive care, such as G-CSF and antibiotics as appropriate.
Half-Life and How Your Body Processes It
After an IV infusion, topotecan is cleared fairly quickly, with a terminal half-life of about 2 to 3 hours. About 35% is bound to plasma proteins. It is changed in the body in a pH-dependent way and into a minor metabolite. The kidneys are an important route of elimination, and most of the drug is cleared in urine and feces. Reduced kidney function slows clearance, which is why doses are adjusted.
Storage
Store at 20° to 25°C (68° to 77°F) . Protect from light; product is light-sensitive.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Supplements and Herbs That Interact With Topotecan
From the licensed clinical database we use, rolled up per supplement, most serious first.19 supplements and herbal products have documented interactions with Topotecan in the licensed clinical database we use.
Most are manageable, but your pharmacist should know about everything you take, including vitamins and herbals.
- 1Major
- 9Moderate
- 9Minor
- ACTIVATED CHARCOALMajor
- COFFEE CHARCOALModerate
- EUROPEAN MANDRAKEModerate
- GLUCOMANNANModerate
- GLUCOSAMINEModerate
- GUAR GUMModerate
- GUM ARABICModerate
- SLIPPERY ELMModerate
Educational information from a licensed clinical database (Natural Medicines). See our data sources and update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Topotecan: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Topotecan — the kind of thing our pharmacy team would talk through with you at the counter.
What is topotecan used for?
How is topotecan given?
What happens if I miss a dose or throw up after taking Hycamtin capsules?
What side effects should I expect, and which ones should I call about?
Why do I need so many blood tests?
Is it safe during pregnancy or breastfeeding?
Is topotecan available over the counter?
When was topotecan first available?
Who makes topotecan?
What is the brand name of topotecan?
What is the generic name of Hycamtin?
What drug class is topotecan?
Is there a generic version of topotecan?
What strengths does topotecan come in?
Is there a topotecan shortage?
Where can I read the topotecan prescribing information (package insert)?
Can you crush topotecan?
Is topotecan gluten free?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Topotecan
Skip the scrolling. Ask in your own words and get an answer from Topotecan’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Topotecan’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Topotecan on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, usually within a day.Topotecan Forms and Strengths (How It Comes)
Topotecan comes in 2 dose forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Topotecan inactive ingredients by manufacturer.
Injection
How this form is used
- Hycamtin for injection and topotecan hydrochloride for injection are used for metastatic ovarian cancer, platinum-sensitive small cell lung cancer, and (with cisplatin) Stage IV-B, recurrent or persistent cervical cancer.
- Topotecan injection products are used for platinum-sensitive small cell lung cancer after first-line chemotherapy.
- Hycamtin for injection is given as an IV infusion over about 30 minutes on a 21-day cycle.
- Topotecan injection concentrate is diluted before being infused over 30 minutes and is handled as a cytotoxic drug.
- Topotecan injection doses are lowered for certain kidney function levels and for severe drops in blood counts.
Capsule
How this form is used
- Hycamtin capsules are used for relapsed small cell lung cancer in people with a prior complete or partial response who are at least 45 days from the end of first-line chemotherapy.
- Hycamtin capsules are taken by mouth once daily for 5 days in a row, starting each 21-day cycle, with or without food.
- Swallow Hycamtin capsules whole. Do not chew, crush or divide them.
- If you miss a Hycamtin dose or vomit after a dose, do not take an extra dose. Take the next dose at the scheduled time.
- Hycamtin capsules should not be given during Grade 3 or 4 diarrhea.
Topotecan on the U.S. Market: Products, Makers and Brands
How Topotecan appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
6 companies list 8 Topotecan product records with the FDA, mostly as injection, capsule; the earliest marketing or approval year on record is 1996. The one brand name in the directory today is Hycamtin; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (2) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How Widely Topotecan Is Used (Medicaid Data)
How many Topotecan prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.
How commonly is Topotecan prescribed? Of the 1,682 medications we measure, Topotecan ranks #1,267 by Medicaid prescriptions — more than 25% of them.
Utilization by Topotecan product
Pick a strength and form to see its own numbers. Brand and generic versions are counted together.
4 ML topotecan 1 MG/ML Injection Most dispensed
1 of 5 listed NDCs had Medicaid claims. RxNorm 1799424
topotecan 4 MG Injection
3 of 8 listed NDCs had Medicaid claims. RxNorm 1799416
topotecan 1 MG Oral Capsule
1 of 2 listed NDCs had Medicaid claims. RxNorm 747193
Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.
Source: Medicaid State Drug Utilization Data (CMS), all states. 5 of the 15 listed Topotecan NDCs had Medicaid claims.
Compare Topotecan Products
A representative set of FDA-listed product records for Topotecan — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Capsule | ||||
| 0.25 mg | Oral | Sandoz Inc | NDA | View NDC → |
| 1 mg | Oral | Sandoz Inc | NDA | View NDC → |
| 💊Injection | ||||
| 4 mg/4 mL | Intravenous | Accord Healthcare, Inc. | ANDA | View NDC → |
| 1 mg/mL | Intravenous | Accord Healthcare Inc. | ANDA | View NDC → |
| 4 mg/4 mL | Intravenous | Actavis Pharma, Inc. | ANDA | View NDC → |
| 4 mg/4 mL | Intravenous | Fresenius Kabi USA, LLC | ANDA | View NDC → |
| 1 mg/mL | Intravenous | Hospira, Inc. | NDA | View NDC → |
| 4 mg/4 mL | Intravenous | Novartis Pharmaceuticals Corporation | NDA | View NDC → |
Showing 8 of 8 products — FDA National Drug Code Directory. See every product, package size and price: browse all 8 Topotecan NDCs →
Topotecan Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Topotecan — a signal of what to watch for, not proof the drug caused it.
The effects most often named in FDA reports that mention Topotecan are febrile neutropenia, anaemia, death; about 92% of the reports were classed as serious. These are voluntary reports, so they show what people report, not how often it happens.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Topotecan in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Topotecan FDA Approval History
How Topotecan went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Topotecan was first approved by the FDA in 1996 (Brand: HYCAMTIN · Sandoz); the first generic version was approved in 2010. It remains available in U.S. pharmacies today.
Source: Drugs@FDA.
Topotecan Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Topotecan recalls since July 2021.
✅No Topotecan recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Topotecan in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.
- Dose forms
- 3
- Strengths
- 5
- Forms in current FDA listings
- 3 of 3
RxCUI 57308 -
Dose form (SCDF) Injectable SolutionIn current FDA listings
RxCUI 376889Its strength (SCD)-
1 mg/mL
RxCUI 637549
-
1 mg/mL
-
Dose form (SCDF) InjectionIn current FDA listings
RxCUI 1799415Its 2 strengths (SCD)-
4 mg
RxCUI 1799416 -
4 mL topotecan 1 mg/mL
RxCUI 1799424
-
4 mg
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Topotecan Supply and Shortage Status
Whether Topotecan is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Topotecan Brand Names
Topotecan has one brand name on record: Hycamtin. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Topotecan: Manufacturers and Labelers
6 companies list Topotecan products with the FDA. By number of product records, the largest are Accord Healthcare Inc., Sandoz Inc, Actavis Pharma, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This Topotecan Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Hospira, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →